Pharmaceuticals
UnitedHealth tops quarterly estimates, hikes profit outlook as insurer manages high medical costs
UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Tuesday posted first-quarter earnings that topped estimates and hiked its 2026 profit outlook, as the company better manages high medical costs and streamlines its operations. The nation’s largest private insurer said it expects […]
Read More
Jim Cramer warns against chasing ‘parabolic’ stocks and says there’s opportunity in overlooked names instead
Key Points CNBC’s Jim Cramer cautioned against chasing “parabolic” tech and AI stocks, warning those trades can quickly reverse. He emphasized the importance of finding opportunities in overlooked names and the need for diversification. CNBC’s Jim Cramer said Monday he’s wary of investors piling into the market’s hottest trades, arguing that chasing “parabolic” moves often […]
Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]
Read More
Trump nominates Erica Schwartz as CDC director amid turmoil around leadership, vaccine policy
Rear Admiral Erica G. Schwartz. U.S. Department of Health and Human Services President Donald Trump on Thursday nominated Erica Schwartz to serve as director of the Centers for Disease Control and Prevention, concluding a monthslong effort to choose a permanent leader of the embattled health agency. Schwartz will have to be confirmed by the Senate, […]
Read More
Cramer’s lightning round: Nokia still has room to run
Stock Chart IconStock chart icon Gilead Sciences’ year-to-date stock performance. Gilead Sciences: “I like what Daniel O’Day is doing…I think he’s a smart guy, and the company’s good. I’d hold on to it. They’ve got some good franchises.” Stock Chart IconStock chart icon AST SpaceMobile’s year-to-date stock performance. AST Space Mobile: “I like it very […]
Read More
J&J tops first-quarter profit estimates even as Stelara sales plunge
Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara. And the company expressed confidence in its just-approved once-daily, oral psoriasis treatment, Icotyde, saying about 1,500 […]
Read More
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday. The partnership will enable Novo to better […]
Read More
Jim Cramer says this is the real reason why stocks are shrugging off Iran war fears
CNBC’s Jim Cramer said Monday that Wall Street’s resilience in the face of escalating geopolitical tensions shows investors are focusing less on the Iran war itself and more on a key driver of stock valuations: interest rates. “I think I’ve been negligent in bringing up the power of low rates, because it’s the reason the […]
Read More
Trump policies, China’s biotech boom are ending Europe’s pharma powerhouse era
Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England. Leon Neal | Getty Images News | Getty Images Once the go-to location for global drugmakers, Europe is now being squeezed by President Donald Trump’s aggressive trade and drug-pricing […]
Read More
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The market share of India’s most popular weight‑loss drugmaker, Eli Lilly, slipped in March, while rival Novo Nordisk held steady even as Indian generic drugmakers flooded the market with lower‑priced copies. Eli Lilly’s Indian market share in the GLP‑1 category of […]
Read More